XML 47 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Schedule of deferred tax assets and liabilities
(in thousands)  2022   2021 
Deferred tax assets:          
Net operating losses carry forward  $44,233   $36,405 
Share-based compensation   1,334    1,213 
Research and development/orphan drug credits   17,247    14,536 
Capitalized research and development expenses   13,210    10,426 
Others   69    19 
Less: valuation allowance   (76,093)   (62,599)
Deferred tax assets, net  $
-
   $
-
 

  

Schedule of difference between income tax provision and U.S federal statutory rates
(in thousands)  December 31,
2022
   December 31,
2021
 
                     
Federal statutory income taxes  $(6,943)   (21.0)%  $(5,202)   (21.0)%
State income taxes   (4,863)   (14.7)%   (373)   (1.5)%
Deferred true-up   89    0.3%   562    2.3%
Research and development/orphan drug tax credit   (2,711)   (8.2)%   (1,898)   (7.7)%
Other   934    2.8%   486    2.0%
Change in valuation allowance   13,494    40.8%   6,425    25.9%
Provision for income tax  $
-
    
-
   $
-
    
-